



How the accreditation process helps us improve

Professor Leonie Young
Scientific Director
Beaumont RCSI Cancer Centre















How has the OECI accreditation process helped us to improve as a Cancer Centre?

> **Cancer Directorate** cancer research

cancer reaearch patients pathway

patient patient outcomes timeframes for patients

way for all patients

practices

cancer centre

patient partnership

cancer specialities

focus set of targets

quality improvement

importance of cancer

A Framework for Cancer Quality



Clear direction

 "It has given us DIRECTION and a clearly defined set of targets to achieve making it easier to compare our service with other institutions"



Culture of Continuous Improvement



Collective effort & shared vision locally & nationally ".....providing focus and direction enabling COLLABORATIVE QUALITY IMPROVEMENTS quality improvement across the cancer centre"

"...we are all working toward a
 COMMON GOAL and we have a shared
 vision in the strategy"




Recognise our great work

- "The process didn't stop once we were accredited it actually gathered momentum"
- "it doesn't feel like a tick box exercise....we are actually changing processes as we go...."
- "It shines a light on the great work we do in Beaumont RCSI Cancer Centre in a formal way...."
- "Has ESTABLISHED OUR REPUTATUION as leaders in quality cancer care"

Presenter Name Title, Departmen











Patient Partnership

- Moving from patient centred to patient partnered
- Putting patients at the highest level of governance in our Cancer Centre
- Developing our centre with patients



"Structure, standardised practice and most importantly the patient partnership...I think having patients involved at multiple levels including the Board and the partnership group is very powerful"





Clinical Care



Clinical Care BEAUMONT RCSI CANCER CENTRE




Cancer Data

- Expanding our cancer data base
- Live real-time dashboard with newly diagnosed and treated patient data
- Facilitates continuous oversight and service planning



Multidisciplinary Structure

- Standardised Multidisciplinary Meetings
- Established annual audit cycle
- Greater engagement & involvement of MDM Chairs with defined roles and responsibilities



Clinical Pathways

- Collective process of coming together to document and formalise our pathways
- 2 consecutive years
 of patient pathway
 measurement for every
 newly diagnosed and newly
 treated patient





Strategic Advice and Performance Monitoring

BEAUMONT RCSI CANCER CENTRE



Research Governance

& Advice





Felix Feng (Chair), UCSF



Asma Nusrat, University of Michigan




Geoffery Greene University Chicago



Alistar Thompson ВСМ



Linda Sharp



Newcastle University Johns Hopkins



Joesphine Feliciano Diether Lambrechts University Leuven



Beaumont RCSI Cancer Centre Research Executive











Research Programmes

BEAUMONT RCSI CANCER CENTRE



Structured **Research Groups** and multidisciplinary research

Breast Cancer



Colorectal Cancer





Gynaecological Cancer





Haematological Cancer





Damir Varešlija Patrick Morris Annette Byrne John Burke Adrian Murphy Tracy Robson Bryan Hennessy

Triona NíChonghalie Siobhan Glavey

Head & Neck Cancer



Robbie Woods

Urological Cancer



Niall Davis Brian O'Neill

Lung Cancer





Jarushka Naidoo Catriona Dowling

Neuro-Oncology





Brona Murphy Stephen McNally Jochen Prehn



Fiachra Martin

Skin Cancers

Upper Gl Cancer



Will Rob

Endocrine & Pan Cancers Endocrine/Pan Cancers & Epidemiology/Public









Marie McIlroy Kathleen Bennett Patrick Redmond Michael O'Reilly



Translational Trial Activity

BEAUMONT RCSI CANCER CENTRE



Current translational research studies in Beaumont RCSI Cancer Centre

Central Nervous System (Biomarkers in Glioma) CTRIAL-IE 08-13

Gastrointestinal (COLOSSUS CTRIAL-IE 17-26),

Breast/cervical (PUMA-NER-9501)

Breast (Proteomics and Molecular Heterogeneity CTRIAL-IE 09-07)

All studies are sponsored by the National Cancer Clinical Trials Network, Caner Trials Ireland. There are currently 4,600 patients on translational research studies in the Cancer Centre.

Cancer translational trial material is now in the process of achieving ISO accreditation (ISO 20387). Accreditation is an internationally recognised system confirming compliance to strict international standards. Beaumont RCSI Cancer Centre translational trials unit is the first national biobank to undergo this accreditation process.



FAUMONT RCSI CANCER CENTRE

Clinical Trial Activity


BEAUMONT RCSI CANCER CENTRE






Presenter Name Title, Department

Numbers of Clinical Trials Open for Accrual in Beaumont RCSI Cancer Centre









Publications BEAUMONT RCSI CANCER CENTRE

Beaumont RCSI Cancer Centre Publications 2018 -2023



Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance






WILEY



2021, Total Publications: **295**, Impact Factor 5-10: **72**, >10: **42** 2022, Total Publications: **273**, Impact Factor 5-10: **59**, >10: **49** 2023, Total Publications: **283**, Impact Factor 5-10: **60** >10: **41**

Publications 2018-2023





Strategic Awards BEAUMONT RCSI CANCER CENTRE



Health Research Board Cancer Trials Ireland; National Cancer Clinical Trials Network - Royal College of Surgeons in Ireland.. Award to Cancer Centre: €7M; 2021

Health Research Board RCSI Cancer Trials Group. Award to Cancer Centre: €2.5M, 2021

Irish Cancer Society. Lung Health Check €5M, 2024

Science Foundation Ireland Strategic Partnership Programme. Multi-omic Longitudinal Mapping of Breast Cancer Brain Metastasis €5.2M, 2024

Science Foundation Ireland ARC for Therapeutics €25M, 2024





















R CFNTRF

Next Steps BEAUMONT RCSI CANCER CENTRE





PROVIDING
PATIENT CARE
INFORMED BY
CUTTING EDGE
RESEARCH IN AN
ENVIRONMENT
THAT PROVIDES
EDUCATION
FOR ALL
RESEARCH
REPORT
2021/2022



begumontrosiconcercentre i

Remain patient partnered in all clinical, educational and research activities

Focus multidisciplinary research on core and emerging areas of strength

Diversify clinical research portfolio – beyond pharmacological intervention to early detection/non-invasive monitoring, surgical and survivorship

Strengthen translational trial activity to drive innovation in investigator initiation clinical trials

Increase patient recruitment to clinical trials





BEAUMONT RCSI CANCER CENTRE